| Autor: |
Lockman, Shahin, Brummel, Sean S, Ziemba, Lauren, Stranix-Chibanda, Lynda, McCarthy, Katie, Coletti, Anne, Jean-Philippe, Patrick, Johnston, Ben, Krotje, Chelsea, Fairlie, Lee, Hoffman, Risa M, Sax, Paul E, Moyo, Sikhulile, Chakhtoura, Nahida, Stringer, Jeffrey SA, Masheto, Gaerolwe, Korutaro, Violet, Cassim, Haseena, Mmbaga, Blandina T, João, Esau, Hanley, Sherika, Purdue, Lynette, Holmes, Lewis B, Momper, Jeremiah D, Shapiro, Roger L, Thoofer, Navdeep K, Rooney, James F, Frenkel, Lisa M, Amico, K Rivet, Chinula, Lameck, Currier, Judith, Best, Brookie M., Blanchette, Cheryl, Browning, Renee, Cheng, Yao, Fox, Andee, Jaliaah, Nagawa, Knowles, Kevin, Mirochnick, Mark, Murtaugh, William A., Patras, Emmanuel, Pinilla, Mauricio, van Wyk, Jean, Whalen, Frances |
| Zdroj: |
The Lancet; April 2021, Vol. 397 Issue: 10281 p1276-1292, 17p |
| Abstrakt: |
Antiretroviral therapy (ART) during pregnancy is important for both maternal health and prevention of perinatal HIV-1 transmission; however adequate data on the safety and efficacy of different ART regimens that are likely to be used by pregnant women are scarce. In this trial we compared the safety and efficacy of three antiretroviral regimens started in pregnancy: dolutegravir, emtricitabine, and tenofovir alafenamide fumarate; dolutegravir, emtricitabine, and tenofovir disoproxil fumarate; and efavirenz, emtricitabine, and tenofovir disoproxil fumarate. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
